STOCK TITAN

scPharmaceuticals Inc - SCPH STOCK NEWS

Welcome to our dedicated news page for scPharmaceuticals (Ticker: SCPH), a resource for investors and traders seeking the latest updates and insights on scPharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect scPharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of scPharmaceuticals's position in the market.

Rhea-AI Summary
scPharmaceuticals Inc. (Nasdaq: SCPH) reported net FUROSCIX revenue of $1.6 million for Q2 2023. They ended the quarter with cash, cash equivalents, and short-term investments of $102.9 million. The company plans to file for NYHA Class IV indication expansion for FUROSCIX by the end of 2023. They also obtained national Medicaid coverage for FUROSCIX effective July 1, 2023. scPharmaceuticals added 10 sales territories, bringing the total field force to 54 territories. They are focused on expanding coverage and favorable formulary placement of FUROSCIX.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
-
Rhea-AI Summary
scPharmaceuticals Inc. (Nasdaq: SCPH) announces positive feedback from the FDA for potential expansion of FUROSCIX® indication to include NYHA Class IV heart failure patients. Additionally, the company has received U.S. patents for alternate furosemide formulations, enabling the development of additional subcutaneous administration options and potential clinical utility in new indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.02%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
-
Rhea-AI Summary
scPharmaceuticals Inc. to host conference call and webcast to discuss financial results for Q1 2023 and provide business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.74%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.14%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
scPharmaceuticals Inc

Nasdaq:SCPH

SCPH Rankings

SCPH Stock Data

177.75M
18.32M
6.59%
75.87%
12.8%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Burlington

About SCPH

scpharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (iv) delivery—with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs.